Submissions from 2017
Molecular hallmarks of cancer: Stemness, T Malta, A Sokolov, A J. Gentles, T Burzykowski, O Gevaert, P W. Laird, Houtan Noushmehr, and M Wiznerowicz
Malignant cerebral edema associated with radiation and laser ablation for brain tumors, Stefania Maraka, Karam Asmaro, Tobias Walbert, and Ian Lee
Trends of hospitalization cost of aneurysmal subarachnoid hemorrhage in the United States, Sumul Modi, Kavit Shah, Muhammad Affan, Rizwan A. Tahir, Panayiotis N. Varelas, and Horia Marin
Epigenomic glioma subtype evaluation across 31 tumor types, M S. Mosella, T Sarraf, T M. Malta, T Chedraoui, Houtan Noushmehr, and Ana V. Castro
Magnetization transfer and T2-weighted MRI studies are useful for visualizing phenotypic presentations of orthotopic, patientderived xenograft mouse models of glioblastoma, Tavarekere N. Nagaraja, Rasha Elmghirbi, Susan M. Irtenkauf, Laura A. Hasselbach, B Tawil, Stephen L. Brown, Swayamprava Panda, Glauber Cabral, Tom Mikkelsen, James R. Ewing, and Ana C. de Carvalho
Raman laser damage threshold of rat pial cortex, Thomas Noh, Michelle Felicella, Laila M. Poisson, Hesham M. Zakaria, Ana C. de Carvalho, B Broadbent, G Auner, and Steven N. Kalkanis
Immunological activation in responding patients with recurrent HGG after treatment with toca 511 & toca FC: Results from a phase 1 trial, Derek Ostertag, William Accomando, D Hogan, Oscar R. Diago, D Gammon, A Haghighi, L Mitchell, M Rodriguez-Aquirre, Timothy Cloughesy, Steven N. Kalkanis, Tom Mikkelsen, J Landolfi, C Chen, Michael A. Vogelbaum, H Gruber, A Das, and D Jolly
Phase 2 trial of SL-701, a novel immunotherapy comprised of synthetic short peptides against GBM targets IL-13ra2, EPHA2, and survivin, in adults with second-line recurrent GBM, D A. Reardon, B Nabors, P Kumthekar, M Badruddoja, K Fink, F Lieberman, J Hu, E Dunbar, Tobias Walbert, D Schiff, J Sherman, D Tran, L S. Ashby, N Butowski, F Iwamoto, C Moertel, M Schulder, J Chen, J Bullington, S Shemesh, C Brooks, T Goswami, and D M. Peereboom
Depletion of 5-hydroxymethylcytosine in aggressive G-CIMP subtype, Thais S. Sabedot, Laila M. Poisson, Ana de Carvalho, and Houtan Noushmehr
Predictive signature of malignant recurrence in G-CIMP tumors, C F. Souza and Houtan Noushmehr
Quantifiable levels of the transgene, cytosine deaminase, in tumor samples following intravenous delivery of toca 511 in patients with recurrent high grade glioma, Tobias Walbert, D Bota, M Vogelbaum, Steven N. Kalkanis, L Liau, Tom Mikkelsen, H Gruber, J S. Shorr, M Rodriguez-Aguirre, Derek Ostertag, L Mitchell, D Jolly, and Timothy Cloughesy
Intravenous delivery of toca 511 in patients with high grade glioma results in quantifiable expression of cytosine deaminase in tumor tissue, Tobias Walbert, D Bota, M Vogelbaum, Steven N. Kalkanis, L Liau, Tom Mikkelsen, H Gruber, J S. Shorr, M Rodriguez-Aquirre, Derek Ostertag, L Mitchell, D Jolly, and Timothy Cloughesy
Deciphering glioma intrinsic transcriptional subtypes identifies tumor evolution associates with changes in immune-microenvironment, Q H. Wang, B L. Hu, X Hu, M Squatrito, Lisa Scarpace, Ana C. de Carvalho, S Lyu, P P. Li, Y Li, F P. Barthel, HJ Cho, Y H. Lin, N Satani, E Martinez-Ledesma, S Y. Zheng, E Chang, A Olar, Z D. Lan, G Finocchiaro, J J. Phillips, M S. Berger, K Gabrusiewicz, G C. Wang, E Eskilsson, J Hu, Tom Mikkelsen, R Depinho, F Muller, A Heimberger, E Sullman, D H. Nam, and R Verhaak
